TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in …

Nov 7, 2024 · TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands …

CouponFollow Extension

6%
OFF

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left In …

1 week from now

Nov 7, 2024 · TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands …

yahoo.com

6%
OFF

TScan Therapeutics, Inc. (TCRX) - Yahoo Finance

1 week from now

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher …

yahoo.com

6%
OFF

TCRX - Tscan Therapeutics Inc Stock Price And Quote - FINVIZ.com

1 week from now

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks) Nov-05-24 09:15AM ... TScan Therapeutics, Inc. discovers and develops transformative T cell therapies …

finviz.com

$500
OFF

TCRX Stock Price | TScan Therapeutics Inc. Stock Quote (U.S.: …

1 week from now

TScan Therapeutics stock soars after Amgen collaboration on Crohn’s disease treatment that could bring in more than $500 million May. 9, 2023 at 9:15 a.m. ET by Tomi Kilgore No …

marketwatch.com

6%
OFF

TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left In The ...

1 week from now

Nov 7, 2024 · TScan Therapeutics, Inc. (TCRX Quick Quote TCRX - Free Report) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with …

zacks.com

6%
OFF

Buy Rating Affirmed: TScan Therapeutics’ Innovative TCR-T Cell ...

1 week from now

Nov 27, 2023 · TScan Therapeutics (TCRX) has received a new Buy rating, initiated by LifeSci Capital analyst, Sam Slutsky. ... TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside …

businessinsider.com

$0.25
OFF

TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses ... - Nasdaq

1 week from now

5 days ago · TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per …

nasdaq.com

$150
OFF

TScan Therapeutics, Inc. (TCRX) - Stock Analysis

1 week from now

Nov 8, 2024 · TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering. WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. …

stockanalysis.com

4%
OFF

Does TScan Therapeutics, Inc. (TCRX) Have The Potential To Rally …

1 week from now

Dec 1, 2023 · Shares of TScan Therapeutics, Inc. (TCRX) have gained 67.4% over the past four weeks to close the last trading session at $6.53, but there could still be a solid upside left in the stock if short ...

yahoo.com

$11.00
OFF

TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating From

1 week from now

3 days ago · TCRX has been the subject of a number of other reports. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of TScan Therapeutics in …

marketbeat.com

FAQs about TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in … Coupon?

How did TSCAN Therapeutics (TCRX) perform in the last trading session?

TScan Therapeutics, Inc. (TCRX) shares soared 7.6% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks. ...

Who owns TSCAN Therapeutics (TCRX)?

The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA. View TScan Therapeutics, Inc. TCRX stock quote prices, financial information, real-time forecasts, and company news from CNN. ...

What is TSCAN Therapeutics?

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. ...

Is TSCAN developing a TCR-T therapy for hematologic malignancies?

The company is developing its lead TCR-T therapy candidates, TSC-100 and TSC-101, in an early-stage study for treating patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. TScan is also developing TCR-T therapy candidates for treating various solid tumors. ...

Where is TSCAN Therapeutics headquartered?

TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is S&P 500 ...

Why did TSCAN's share price rally?

TScan is also developing TCR-T therapy candidates for treating various solid tumors. The growing optimism about the company’s pipeline candidates might have driven the recent share price rally. ...